ArticleJournal of ophthalmic inflammation and infection2026
Secondary punctate inner choroidopathy in an RP2 associated retinopathy female carrier.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe a case of punctate inner choroidopathy (PIC) occurring in a RP2 associated Retinopathy female carrier, highlighting the diagnostic contribution of multimodal imaging and the therapeutic course.
methodsObservational case report with multimodal retinal imaging, electrophysiology, and genetic testing.
resultsA 46-year-old woman with high myopia (- 8 diopters in both eyes) and a right Adie's pupil presented with a shadow-like visual disturbance in the right eye (RE). Family history was notable for X-linked retinitis pigmentosa: her brother was hemizygous for the pathogenic RP2 variant c.1 A > G (p.Met1?), and her mother was a heterozygous carrier with light perception vision in both eyes. At presentation, best-corrected visual acuity (BCVA) was 20/32 in the RE and 20/20 in the left eye (LE). Fundus examination revealed diffuse chorioretinal atrophy and multiple punched-out lesions, predominantly nasal, with some macular involvement suggestive of inactive PIC. Subtle peripheral bone spicules were also observed. Fundus autofluorescence (FAF) demonstrated hypoautofluorescent lesions corresponding to the punched-out scars and radial hyperautofluorescent streaks around the posterior pole, a characteristic pattern of X-linked RP carriers. Flash electroretinography revealed bilateral rod and cone dysfunction, more pronounced in the LE. Genetic testing confirmed the heterozygous RP2 c.1 A > G variant, establishing the patient as an X-linked RP carrier. Two years later, the patient developed a new greyish inflammatory lesion in the papillomacular bundle of the RE. OCT demonstrated hyperreflective subretinal material disrupting the RPE with posterior hypertransmission, consistent with an acute PIC lesion. She was treated with systemic corticosteroids and methotrexate. Subsequent flares required treatment escalation, including mycophenolate mofetil and later a combination of methotrexate and adalimumab due to intolerance. One year after initiating biologic therapy, the patient remains in remission with stable visual acuity (20/32 RE, 20/25 LE).
conclusionsSecondary PIC may occur in carriers of X-linked RP. Multimodal imaging and genetic testing are essential for accurate characterization, and immunosuppressive therapy can achieve sustained disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.